Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

East To Meet West On Cardiovascular Clinical Trial Design

This article was originally published in The Gray Sheet

Executive Summary

FDA and Japanese regulatory authorities will meet in January to discuss a project for establishing "global" cardiovascular device clinical studies capable of satisfying approval requirements in both countries

You may also be interested in...



People In Brief

Novasys Medical CEO: Renessa non-surgical stress urinary incontinence device maker tapped Scott Cramer as its new CEO last week to replace the departing Debra Reisenthel. Cramer was formerly CEO of peripheral vascular device firm Bacchus Vascular, which Covidien acquired in 2009. Prior to Bacchus, Cramer was a senior VP with varicose vein treatment firm VNUS Medical Technologies, which was also purchased by Covidien last year (1"The Gray Sheet" May 11, 2009). Reisenthel was a nine-year veteran of Novasys. She is pursuing a "position where I can use my leadership and fundraising skills to 'make a difference' and improve people's lives," she says

People In Brief

Novasys Medical CEO: Renessa non-surgical stress urinary incontinence device maker tapped Scott Cramer as its new CEO last week to replace the departing Debra Reisenthel. Cramer was formerly CEO of peripheral vascular device firm Bacchus Vascular, which Covidien acquired in 2009. Prior to Bacchus, Cramer was a senior VP with varicose vein treatment firm VNUS Medical Technologies, which was also purchased by Covidien last year (1"The Gray Sheet" May 11, 2009). Reisenthel was a nine-year veteran of Novasys. She is pursuing a "position where I can use my leadership and fundraising skills to 'make a difference' and improve people's lives," she says

Opening The “Black Box” Of Japanese Medical Device Review – An Interview With Kaye Suzuki

Europe, United States, Japan: For medical device companies seeking an international market, this is a well-trod path

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT024258

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel